Quality Systems – Page 259

Fill Weight Variability in dental paste filling: manufacturing vs lab root cause assessment

Root Cause Analysis of Fill Weight Variability in Dental Paste Manufacturing Fill weight variability in dental paste filling poses significant challenges for pharmaceutical manufacturers, potentially leading to deviations and nonconformance…

Phase Separation in dental paste filling: manufacturing vs lab root cause assessment

Root Cause Investigation for Phase Separation in Dental Paste Filling During Manufacturing and Lab Assessments In the pharmaceutical manufacturing of dental dosage forms, particularly dental paste fillings, phase separation can…

Tube Leakage Complaint in dental paste filling: packaging compatibility and shelf-life justification

Addressing Tube Leakage Issues in Dental Paste Filling: An Investigation Framework Complaints concerning tube leakage in dental paste filling can significantly impact product quality and shelf life, necessitating a thorough…

Assay Oos during line setup: investigation steps with CAPA evidence

Investigation Steps for Assay OOS During Line Setup in Pharmaceutical Manufacturing In the fast-paced world of pharmaceutical manufacturing, deviations from expected assay results can trigger significant operational challenges, especially during…

Microbial Limits Failure in dental paste filling: GMP investigation steps with CAPA

Investigating Microbial Limits Failure in Dental Paste Filling: A GMP Approach with CAPA Microbial limits failures in dental paste filling are a significant concern within pharmaceutical manufacturing, particularly when it…

Pet Failure after packaging change: manufacturing vs lab root cause assessment

Root Cause Assessment for Pet Failure Following a Packaging Change in Pharmaceuticals The pharmaceutical manufacturing industry often faces challenges when packaging changes are implemented, leading to unexpected quality issues in…

Hold Time Bioburden Rise after supplier change: GMP documentation for FDA/EMA/MHRA review

Investigation of Increased Bioburden Hold Times Following a Supplier Change Bioburden testing is pivotal in ensuring the quality and safety of pharmaceuticals, particularly in sterile environments. After a recent supplier…

Viscosity Drift at accelerated stability: packaging compatibility and shelf-life justification

Investigating Viscosity Drift During Accelerated Stability Testing: Ensuring Packaging Compatibility and Shelf-Life Justification Viscosity drift observed during accelerated stability tests can indicate underlying issues impacting product quality and regulatory compliance…

Tube Leakage Complaint after supplier change: QMS trending and complaint handling expectations

Addressing Tube Leakage Complaints Following Supplier Changes in Pharmaceutical Manufacturing In the pharmaceutical manufacturing environment, changes in suppliers can lead to unforeseen issues, including product complaints such as tube leakage.…

Content Uniformity Failure during method transfer: sampling and mixing controls for QA review

Addressing Content Uniformity Failures during Method Transfer: A Comprehensive Investigation Guide Content uniformity failures during method transfer can present significant challenges in pharmaceutical manufacturing, especially in quality assurance. Such failures…

Viscosity Drift during method transfer: GMP documentation for FDA/EMA/MHRA review

Understanding Viscosity Variations during Method Transfers: A Guide for Pharmaceutical Professionals Viscosity drift during method transfer can compromise product quality and regulatory compliance. It may arise from process modifications, equipment…

Assay Oos after supplier change: manufacturing vs lab root cause assessment

Investigating Assay OOS After a Supplier Change: A Comprehensive Approach In the realm of pharmaceutical manufacturing, an Out of Specification (OOS) result, especially concerning assays, can trigger significant concern and…